**Supplementary Figure 1.** Treatment efficacy outcomes (A) and PROMs scores reduction after 3-months of mAb treatment.

Abbreviations: PROM: patient-reported outcome measure; d/mo: days per month; p/mo: pills per month; MHD: monthly headache days; MMD: monthly migraine days; INT: headache pain intensity; AMD: days of acute medication intake; AMP: acute medication burden or pills/month; MO: medication overuse; MIDAS: migraine disability assessment; HIT-6: headache impact test; MSQ$_T$: migraine-specific quality of life questionnaire (total score); BAI: Beck anxiety inventory; BDI-II: Beck depression inventory-second edition; MIG-SCOG: migraine attacks-subjective cognitive impairment scale.

**Supplementary Figure 2.** Relative changes (%Δ) from treatment efficacy outcomes (A) and PROMS questionnaires scores (B) after 3-months of mAb treatment between patients who continued treatment (GO) and patients who discontinued it (No-GO)



*P-value < 0.05; **P-value < 0.001; ***P-value < 0.0001; ns: no statistically significant

§Significance assessed with Fisher's exact test

†Significance assessed with independent *t*-test

‡Significance assessed with independent Mann-Whitney U test

Abbreviations: MHD: monthly headache days; MMD: monthly migraine days; INT: headache pain intensity; AMD: days of acute medication intake; AMP: acute medication burden or pills/month; MO: Medication Overuse; MIDAS: migraine disability assessment; HIT-6: headache impact test; MSQ$_T$: migraine-specific quality of life questionnaire (total score); BAI: Beck anxiety inventory; BDI-II: Beck depression inventory-second edition; MIG-SCOG: migraine attacks-subjective cognitive impairment scale.

**Supplementary Figure 3.** Relative changes (Δ%) associations between treatment efficacy outcomes improvement and PGI-C.



\*\*\*P-value < 0.0001

§Significance assessed with Fisher's exact test

†Significance assessed with independent *t*-test

‡Significance assessed with independent Mann-Whitney U test

Abbreviations: MHD: monthly headache days; MMD: monthly migraine days; INT: headache pain intensity; AMD: days of acute medication intake; AMP: acute medication burden or pills/month; MO: Medication Overuse; PGI-C: patient global impression scale